Skip to Content

Brainstorm Cell Therapeutics Inc.

Securities Class Action

  • Date:
  • 1/2/2024
  • Company Name:
  • Brainstorm Cell Therapeutics Inc.
  • Stock Symbol:
  • BCLI
  • Class Period:
  • FROM 8/15/2022 TO 9/27/2023
  • Status:
  • Filed
  • Filing Date:
  • 11/1/2023
  • Court:
  • U.S. District Court: Southern District of New York

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Brainstorm Cell Therapeutics Inc. (“Brainstorm Cell” or the “Company”) (NASDAQ: BCLI) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Brainstorm Cell securities between August 15, 2022 and September 27, 2023, both dates inclusive (the “Class Period”). Investors have until January 2, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

According to the lawsuit, throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Brainstorm Cell downplayed the severity of the Food and Drug Administrations (FDA) refusal to file letter; (2) Brainstorm Cell continued to conceal the risks associated with the submission of the biologics license application (BLA); and (3) as a result, Defendants statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

If you purchased or otherwise acquired Brainstorm Cell shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out the form below.  There is no cost or obligation to you.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Brainstorm Cell Therapeutics Inc.. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: